The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PBM | -90.99% | N/A | N/A | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +46% |
Psyence Biomedical Ltd. is a life science biotechnology company. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on June 29, 2023 and is headquartered in Toronto, Canada.
No news articles found for Psyence Biomedical.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | -30.9% |
| Market Cap | $2.28M | -49.8% |
| Net Income | -$0.75M | -632.4% |
| EBITDA | -$1.50M | -30.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.20M | 266.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | 122.01% | -35.7% |
No data available for this period.
| Metric | Q3 2024 | Q3 2025 | YoY Change |
|---|---|---|---|
| Price to Book | -3.62 | -0.19 | - |
| Price to Tangible Book Value | -150.22 | -0.19 | - |
| Enterprise Value to EBITDA | -0.14 | 1.63 | - |
| Total Debt | $0.05M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
